Trial of Adalimumab in Progressive Sarcoidosis

NCT00311246 | Terminated Phase 2 Results DMC

• 1 other identifier: University of Chicago #14093A
• Study Type: interventional
• Target: 11
• Locations: 1 country
• Sites: 1

Brief Summary

Sarcoidosis is a rare disease that can affect any organ in the body. It is characterized by the buildup of immune-system (fights off infection in the body) cells in organs. These cells form small groups called granulomas, which lead to inflammation of the surrounding tissue. Sarcoidosis most commonly affects the lung and the lymph nodes (part of the immune system). The signs usually include shortness of breath, fever, dry cough, and chest pain. Other signs in many patients can include redness and painful lumps on the skin, reduced eyesight, joint pain, and rarely, nervous system damage. Sarcoidosis commonly affects young and middle-aged adults. There are no approved therapies for the treatment of sarcoidosis. Corticosteroid (steroid hormone) therapy is considered the standard treatment. Only limited benefit has been shown when using corticosteroid therapy to ease lung symptoms or improve lung function in patients with sarcoidosis. Also, the effects of other therapies (for example: methotrexate, cyclophosphamide, anti-malarial drugs, thalidomide) and other immunosuppressants (drugs that suppress a body's natural defense system \[immune system\]) which have been used in a small number of patients are not well known and can cause long term problems. The drug used in this study is called adalimumab. Adalimumab is FDA (Food and Drug Administration) approved for patients with moderately to severely active rheumatoid arthritis. However, adalimumab is not approved for the treatment of sarcoidosis. Adalimumab is experimental in this study. The purpose of this study is to evaluate the safety and effectiveness of adalimumab in the treatment of patients with sarcoidosis with pulmonary (lung) involvement who show symptoms of the disease even though they are currently being treated with medication.

Conditions

Sarcoidosis

Keywords

Sarcoidosis; Humira; Adalimumab; Tumor Necrosis Factor Inhibitors

Outcome Measures

Primary Outcomes (1)

• Change in FVC From Screening to Week 24

  The forced vital capacity (FVC) measurement shows the amount of air a person can forcefully and quickly exhale after taking a deep breath. Improvement in FVC, if significant, means better breathing and lung function. The change in FVC done at screening and at week 24 were compared to notice if there were any changes.

  24 Weeks

Secondary Outcomes (4)

• Change in Distance Walked During 6 Minute Walk Test at Screening and 24 Weeks

  24 weeks

• A Change in the Borg Dyspnea Score Before/After the 6 Minute Walk at Screening (S) and at 24 Weeks (W).

  24 weeks

• Physicians Global Assessment of Disease Activity.

  24 weeks

• Patient's Global Assessment of Disease Activity.

  24 weeks

Study Arms (1)

An open-label

EXPERIMENTAL

Patients received adalimumab 40 mg weekly for 45 weeks, with a final follow-up at Week 52

Drug: Adalimumab

Interventions

Adalimumab DRUG

Subjects will give themselves a dose of Adalimumab at 40 mg/every week by subcutaneous injection for a total of 45 weeks.

Also known as: Humira

An open-label

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Men and women \> 18 years of age.
• Sarcoidosis diagnosed at least 1 year prior to screening.
• Histologically proven sarcoidosis prior to screening.
• Have a diagnosis of sarcoidosis with evidence of parenchymal disease on chest radiograph (Stage II or III) or Stage I disease by chest radiographs and evidence of abnormal PFT as below or normal chest radiograph; or abnormal PFT, with abnormal chest computed tomography (CT) and evidence of sarcoid lung involvement by histology. Subjects with concurrent extrapulmonary sarcoidosis, particularly skin and eye involvement, are encouraged to be enrolled.
• Have forced vital capacity (FVC) \> 40 and \< 80% of predicted.
• Have an American Thoracic Society (ATS) dyspnea score of \> Grade 1.
• Have been receiving pre-study treatment that includes at least 10 mg/day prednisone (or equivalent dose of corticosteroid) as a single agent, or 1 or more immunosuppressant (e.g., methotrexate, azathioprine, cyclophosphamide, chloroquine, leflunomide, hydroxychloroquine, mycophenolate mofetil, cyclosporine, tacrolimus, corticosteroids) for at least the 3-month period immediately prior to screening. Subjects must be on a stable dose of these medications for \> 4 weeks before starting the study medication.
• Adequate birth control measures (e.g., abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, or surgical sterilization) must be used for the duration of the study and such precautions should be continued for 6 months after receiving the last study agent injection.
• Are considered eligible based on TB screening

You may not qualify if:

• Have used any investigational drug within 1 month prior to screening.
• Have received previous administration of a treatment with any other therapeutic agent targeted at reducing tumor necrosis factor \[TNF\] (e.g., pentoxifylline, thalidomide, etanercept, infliximab) within 3 months prior to screening.
• Have received previous administration of adalimumab.
• Have received any live virus or bacterial vaccinations within the 3 months before the first dose of the study agent or are expected to receive any live virus or bacterial vaccinations during the trial or up to 3 months after the last dose of the study agent.
• Have had any previous adverse reactions or allergic reactions (e.g., anaphylaxis) associated with the administration of monoclonal antibodies.
• Have New York Heart Association (NYHA) Class III or IV congestive heart failure (CHF).
• Have a history of severe right-sided heart failure or cor pulmonale.
• Are considered ineligible according to the United States of America (USA)-specific TB screening.
• Have or have had an opportunistic infection (e.g., herpes zoster \[shingles\], cytomegalovirus, Pneumocystis carinii, aspergillosis and aspergilloma, histoplasmosis, or mycobacteria other than TB) within 6 months prior to screening.
• Have a known infection with human immunodeficiency virus (HIV).
• Have current signs and symptoms of systemic lupus erythematosus, or severe, progressive, or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurologic, or cerebral diseases (with the exception of sarcoidosis).
• Presence of a transplanted organ (with the exception of a corneal transplant) \> 3 months prior to screening.
• Have any known malignancy or history of malignancy within 5 years prior to screening.
• Have a history of lymphoproliferative disease including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease.
• Are pregnant, nursing, or planning pregnancy (both men and women) during the trial or within the 6-month period thereafter.

Sponsors & Collaborators

• University of Chicago: lead
• Abbott: collaborator

Study Sites (1)

The University of Chicago

Chicago, Illinois, 60637, United States

Location

Related Publications (1)

• Sweiss NJ, Noth I, Mirsaeidi M, Zhang W, Naureckas ET, Hogarth DK, Strek M, Caligiuri P, Machado RF, Niewold TB, Garcia JG, Pangan AL, Baughman RP. Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2014 Apr 18;31(1):46-54.

  PMID: 24751453 DERIVED

Related Links

• Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis.

MeSH Terms

Conditions

Sarcoidosis

Interventions

Adalimumab

Condition Hierarchy (Ancestors)

Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Hypersensitivity, Delayed; Hypersensitivity; Immune System Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Results Point of Contact

• Title: Nadera J Sweiss
• Organization: UIC

nsweiss@uic.edu

312-996-5723

Study Officials

• Nadera J. Sweiss, M.D.

  The University of Chicago Hospitals

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 3, 2006
• First Posted: April 5, 2006
• Study Start: April 1, 2006
• Primary Completion: May 1, 2008
• Study Completion: September 1, 2008
• Last Updated: August 25, 2020
• Results First Posted: August 14, 2020

Record last verified: 2020-03

Locations

US (1)